All In Biotech

NDA 209379 · Am Regent

Selenious Acid

Selenious Acid · Intravenous

Priority review

Last checked: Nov 20, 2026Latest source record: Aug 30, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2019

Apr 30, 2019

Approved uses

1

Original approval plus efficacy supplements

Registered trials

15

5 Phase 3, 0 recruiting

FAERS reports

12

11 serious, 1 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 1, 2021.

Selenious Acid Injection is indicated in adult and pediatric patients as a source of selenium for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated. Selenious Acid Injectionis a trace element indicated in adult and pediatric patients as a source of selenium for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated. ( 1 )

Mechanism: Selenious acid is converted in vivo to hydrogen selenide via glutathione-involved electron reductions. Hydrogen selenide acts as a selenium pool to form selenoproteins which include, but are not limited to, glutathione peroxidase, iodothyronine deiodinase, peroxidase and thioredoxins.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Apr 30, 2019 Original approval · Type 2 - New Active Ingredient · priority review LabelLetterReview
3 products under this application
  • SELENIOUS ACID · SELENIOUS ACID EQ 60MCG SELENIUM/ML (EQ 60MCG SELENIUM/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP
  • SELENIOUS ACID · SELENIOUS ACID EQ 12MCG SELENIUM/2ML (EQ 6MCG SELENIUM/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP
  • SELENIOUS ACID · SELENIOUS ACID EQ 600MCG SELENIUM/10ML (EQ 60MCG SELENIUM/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Selenious Acid" as an intervention, any sponsor and status, largest first.

All 15 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • plasma cell myeloma5
  • diarrhoea2
  • cerebral palsy1
  • cholangitis1
  • circumstance or information capable of leading to medication error1
  • fatigue1
  • hypersensitivity1
  • infection1
  • internal haemorrhage1
  • nausea1
  • neuropathy peripheral1
  • pneumonia1

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20121
20141
20171
20201
20234
20242
20262

Recalls

1 FDA enforcement reports for this application.

  • Jul 24, 2026 · Class II · Ongoing

    Presence of Particulate Matter: Product contaminated with particulate matter identified as hair, glass and/or paraformaldehyde

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 4 on PubMed

Sponsor: Am Regent

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.